The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Small Interfering Ribonucleic Acid (RNA) Market Over The 2026–2030 Period?
The small interfering ribonucleic acid (rna) market size has shown substantial growth in recent times. It is anticipated to expand from $18.86 billion in 2025 to $22.69 billion in 2026, at a compound annual growth rate (CAGR) of 20.3%. Factors contributing to its historical growth include progress in molecular biology research, the increasing occurrence of genetic and chronic diseases, the initial successes of rna-based therapeutics, augmented research funding in genomics, and the establishment of rna interference mechanisms.
The small interfering ribonucleic acid (RNA) market is projected to experience substantial expansion in the coming years. This market is forecast to reach a valuation of $47.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.0%. This anticipated growth during the forecast period is propelled by factors such as a rise in regulatory clearances for RNA-based treatments, escalating demand for tailored medical solutions, advancements in nanoparticle delivery systems, heightened financial commitments from pharmaceutical firms, and wider utilization of siRNA in managing infectious and uncommon diseases. Key trends expected over the forecast horizon encompass the increasing clinical integration of RNA interference treatments, a heightened emphasis on specific gene silencing methodologies, the proliferation of sophisticated siRNA delivery technologies, increased funding for the creation of precision therapeutics, and a stronger focus on developing scalable RNA production methods.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30394&type=smp
What Drivers Are Expected To Influence The Small Interfering Ribonucleic Acid (RNA) Market During The Forecast Period?
The increasing need for personalized medicine is anticipated to drive the expansion of the small interfering ribonucleic acid (RNA) market in the future. Personalized medicine refers to a healthcare strategy where treatments are customized for each patient, considering their genetic makeup, environmental influences, and lifestyle choices, to enhance results and patient care. Growth in genomic technologies, which allow for accurate identification of genetic differences and personalized therapies, is fueling the rising demand for personalized medicine. Small interfering ribonucleic acid (siRNA) contributes to personalized medicine through its ability to perform targeted gene silencing, making it highly suitable for addressing particular genetic conditions and illnesses. By precisely suppressing disease-causing mRNA, it minimizes unintended effects, thereby boosting therapeutic effectiveness and patient results. For example, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit, released in February 2024, showed that the U.S. Food and Drug Administration (FDA) cleared 26 new personalized medicines in 2023, marking a considerable rise from the 12 approved in 2022. Consequently, the growing demand for personalized medicine is propelling the expansion of the small interfering ribonucleic acid (RNA) market.
How Is The Small Interfering Ribonucleic Acid (RNA) Market Segmented Across Key Categories?
The small interfering ribonucleic acid (rna) market covered in this report is segmented –
1) By Type: Liposome Systemic Therapy, Nanoparticle-Based Systemic Therapy
2) By Indication: Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases
3) By End-User: Hospital, Research Institutions, Pharmaceutical And Biotechnology Companies, Academic Institutions
Subsegments:
1) By Liposome Systemic Therapy: Cationic Liposome Delivery, Neutral Liposome Delivery, Pegylated Liposome Delivery, Targeted Liposome Delivery
2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery, Polymer Nanoparticle Delivery, Gold Nanoparticle Delivery, Silica Nanoparticle Delivery
Which Upcoming Trends Are Expected To Influence The Small Interfering Ribonucleic Acid (RNA) Market?
Leading companies active in the small interfering ribonucleic acid (siRNA) therapeutics market are concentrating on obtaining regulatory clearances for innovative mechanisms aimed at treating rare genetic conditions, with the objective of providing lasting effects and decreasing the dosing frequency for patients. Regulatory approvals signify official authorizations from authorities that permit a drug or therapy to be safely tested, marketed, or utilized in patients. For instance, in March 2025, Alnylam Pharmaceuticals Inc., a US-based biopharmaceutical enterprise, secured approval from the U.S. Food and Drug Administration (FDA) for Qfitlia (fitusiran), which is the first small interfering ribonucleic acid (siRNA)-based therapy for adults and adolescents aged 12 years and older diagnosed with hemophilia A or B, regardless of inhibitor status. This therapy is formulated to decrease antithrombin levels, thereby boosting thrombin generation to facilitate clot formation and lessen bleeding episodes. Qfitlia provides a subcutaneous, once-every-two-month dosing regimen, offering an innovative, non-factor therapeutic choice for managing hemophilia.
Who Are The Dominant Players Shaping The Small Interfering Ribonucleic Acid (RNA) Market Landscape?
Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.
Read the full small interfering ribonucleic acid (rna) market report here:
Which Region Is Forecast To Lead The Small Interfering Ribonucleic Acid (RNA) Market In Terms Of Market Size?
North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2025. The regions covered in the small interfering ribonucleic acid (rna) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Small Interfering Ribonucleic Acid (RNA) Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=30394&type=smp
Browse Through More Reports Similar to the Global Small Interfering Ribonucleic Acid (RNA) Market 2026, By The Business Research Company
Ribonucleic Acid Rna Sequencing Market Report 2026
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Nucleic Acid Isolation And Purification Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model